⚡ Flash Summary

Liven Pharma Limited has announced its 34th Annual General Meeting (AGM) to be held on November 26, 2025, to confirm minutes, adopt financial statements for the year ended June 30, 2025, and appoint auditors for the year ending June 30, 2026. The meeting will address ordinary business, including auditor re-appointment. Special business includes the approval for circulation of the annual report via weblink and QR code, aligning with regulatory requirements. Shareholders are encouraged to participate electronically, with specific procedures outlined for registration, proxy appointments, and e-voting.

📌 Key Takeaways

• 🗓️ The 34th AGM will be held on **November 26, 2025**, at 11:00 AM.
• 📍 The meeting will take place at the company’s registered office at **49-km Lahore-Multan Road, Pakistan**.
• ✔️ Agenda includes confirming the minutes of the previous AGM held on **October 25, 2024**.
• 📄 Shareholders will receive and consider the Annual Audited Financial Statements for the year ended **June 30, 2025**.
• 👨‍💼 Auditors will be appointed for the year ending **June 30, 2026**, with their remuneration to be fixed.
• ✅ Re-appointment of retiring auditors **M/s. Reanda Haroon Zakaria Aamir Salman Rizwan & Company** is recommended.
• 🌐 The annual report will be circulated through a **weblink and QR enabled code**.
• 🔗 The Annual Report for the year ended June 30, 2025 is available on the company’s website.
• 🚫 Share transfer books will be closed from **November 19, 2025 to November 26, 2025**.
• ✉️ Transfers must be received by **5 pm on November 18, 2025**, to be treated in time.
• 🗳️ Members appearing in the register as of **November 18, 2025**, are entitled to attend and vote.
• 🤝 Members can appoint a proxy, with forms to be deposited **48 hours before the meeting**.
• 💻 Shareholders can attend via video-conferencing; registration required via email.
• 📧 Email addresses for registration and inquiries: **info@liven-pharma.com and fdregistrar@yahoo.com**.

🎯 Investment Thesis

Based solely on this announcement, a HOLD recommendation is appropriate. The AGM is a routine event, and the focus remains on governance and compliance rather than strategic initiatives. A more informed investment decision would require a detailed analysis of the adopted financial statements, management’s outlook, and other relevant factors. A price target and timeline cannot be determined without further financial information.